The significance of the HER-2 status in esophageal adenocarcinoma for survival: An immunohistochemical and an in situ hybridization study

Annals of Oncology

Volumn 24, Issue 5, 2013, Pages 1290-1297

  Prins, M J D ^a   Ruurda, J P ^a   van diest, P J ^a   van Hillegersberg, R ^a   ten kate, F J W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Esophageal adenocarcinoma; Gene amplification; HER 2; Protein

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 84877137684     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds640     Document Type: Article

References (32)

1. Siegel R, Ward E, Brawley O et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61(4): 212-36.
2. Sjoquist KM, Burmeister BH, Smithers BM et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12(7): 681-92.
3. van HP, Hulshof MC, Van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366(22): 2074-84.
4. Wilson CA, Cajulis EE, Green JL et al. HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells. Breast Cancer Res 2005; 7(6): R1058-R1079.
5. Ben-Levy R, Paterson HF, Marshall CJ et al. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J 1994; 13(14): 3302-11.
6. Bang YJ, Van CE, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376(9742): 687-97.
7. Blair AJ, Charles RT, John GH. Esophageal Cancer: Principles and Practice. New York, NY: Demos Medical Publishing 2009.
8. Herceptin: EPAR-Product information: European Medicines Agency. 1-3-2010. 29-5-2012.
9. Flejou JF, Paraf F, Muzeau F et al. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J Clin Pathol 1994; 47(1): 23-6.
10. Langer R, Rauser S, Feith M et al. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Mod Pathol 2011; 24(7): 908-16.
11. Brien TP, Odze RD, Sheehan CE et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol 2000; 31(1): 35-9.
12. Nakamura T, Nekarda H, Hoelscher AH et al. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 1994; 73(7): 1785-94.
13. Hardwick RH, Barham CP, Ozua P et al. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol 1997; 23(1): 30-5.
14. Hu Y, Bandla S, Godfrey TE et al. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol 2011; 24(7): 899-907.
15. Kunz PL, Mojtahed A, Fisher GA et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012; 20(1): 13-24.
16. Schoppmann SF, Jesch B, Friedrich J et al. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol 2010; 34(12): 1868-73.
17. Thompson SK, Sullivan TR, Davies R et al. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. Ann Surg Oncol 2011; 18(7): 2010-7.
18. Chan DS, Twine CP, Lewis WG. Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. J Gastrointest Surg 2012; 16(10): 1821-9.
19. Verhage RJ, Zandvoort HJ, ten Kate FJ et al. How to define a positive circumferential resection margin in T3 adenocarcinoma of the esophagus. Am J Surg Pathol 2011; 35(6): 919-26.
20. Mariette C, Taillier G, Van SI et al. Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma. Ann Thorac Surg 2004; 78(4): 1177-83.
21. Edge SB, Byrd DR, Compton CC et al. AJCC Cancer Staging Manual, 7th edition. New York, NY: Springer 2010.
22. Boone J, van Hillegersberg R, van Diest PJ et al. Validation of tissue microarray technology in squamous cell carcinoma of the esophagus. Virchows Arch 2008; 452(5): 507-14.
23. Bartlett JM, Going JJ, Mallon EA et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001; 195(4): 422-8.
24. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52(7): 797-805.
25. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 2011; 58(3): 383-94.
26. Tafe LJ, Janjigian YY, Zaidinski M et al. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Arch Pathol Lab Med 2011; 135(11): 1460-5.
27. Seidenfeld J, Samson DJ, Rothenberg BM. HER2 Testing to Manage Patients With Breast Cancer or Other Solid Tumors. Rockville: Agency for Healthcare Research and Quality 2008.
28. Moelans CB, de Weger RA, van Diest PJ. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res Treat 2010; 120(1): 1-7.
29. Ruschoff J, Hanna W, Bilous M et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012; 25(5): 637-50.
30. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365(14): 1273-83.
31. Safran H, Dipetrillo T, Akerman P et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007; 67(2): 405-9.
32. Gravalos C, Gomez-Martin C, Rivera F et al. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol 2011; 13(3): 179-84.